Appia Bio Inks Mega Deal To Scale Cancer Therapies

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

Appia Bio Inks Mega Deal To Scale Cancer Therapies

The next wave of cancer treatments uses the body's own immune system rather than chemotherapy or radiation to kill cancer cells. Treatments are being developed by two Southern California pharma companies.

Last week, one of the biggest players in cell therapy, Kite Pharma, announced it will work with the cancer startup Appia Bio to create breakthrough drugs.


Under the agreement, Westwood-based Appia Bio (which came out of stealth in May) and Kite Pharma will develop CAR-T cell therapies, a promising new treatment that aims to eliminate cancer cells and strengthen the immune system's response to flag and fight these cells in the future. The deal could be worth up to $875 million for Appia Bio, according to the two companies.

The deal highlights a growing, collaborative ecosystem in Los Angeles reminiscent of the biotech community in San Diego. Pharma giant Gilead Sciences announced in 2017 it would acquire Kite Pharma in a nearly $12 billion deal, pointing to a growing interest in Los Angeles' bioscience community made up of university-to-startup pipelines like Appia, which has founders from UCLA, USC and CalTech.

Appia Bio will be responsible for doing preclinical and early clinical research of engineered cells provided by Kite, and Kite Pharma will be responsible for developing, manufacturing and commercializing the therapies.

Unlike most cell therapies that come from cells of the patient, known as autologous cell therapy, Appia Bio will use the cells of other people, known as allogeneic cell therapy. The company's patented technology, ACUA, uses allogeneic cells to generate iNKT cells, which may be less likely to be rejected by the patient's immune system.

"We hope to provide allogeneic cell therapy as a broadly accessible next-generation therapeutic option for oncologists and their patients," said Appia Bio CEO JJ Kang in an email.

Appia Bio hopes this will create safe therapies at scale, allowing doctors to start treatment almost immediately instead of making late-stage cancer patients wait long time periods as their cells are engineered.

Kang said they partnered with Kite because it already had manufacturing facilities as well as an infrastructure for development and research.

This isn't Kite Pharma's first foray into CAR-T cell therapies. The FDA approved one of the pharma company's CAR-T treatments for a type of lymphoma cancer in 2017, and another was approved for what's known as mantle cell lymphoma cancer last year.

https://twitter.com/KeerthiVedantam
keerthi@dot.la

Subscribe to our newsletter to catch every headline.

LA-Based Apex Is Tapping Into the Small Satellite Market by Making Buses for Spacecraft

Spencer Rascoff

Spencer Rascoff serves as executive chairman of dot.LA. He is an entrepreneur and company leader who co-founded Zillow, Hotwire, dot.LA, Pacaso and Supernova, and who served as Zillow's CEO for a decade. During Spencer's time as CEO, Zillow won dozens of "best places to work" awards as it grew to over 4,500 employees, $3 billion in revenue, and $10 billion in market capitalization. Prior to Zillow, Spencer co-founded and was VP Corporate Development of Hotwire, which was sold to Expedia for $685 million in 2003. Through his startup studio and venture capital firm, 75 & Sunny, Spencer is an active angel investor in over 100 companies and is incubating several more.

​Ian Cinnamon
Ian Cinnamon

On this episode of Office Hours, Apex founder and CEO Ian Cinnamon discusses the importance of investing in space exploration and shares his thoughts on the evolving space ecosystem in Los Angeles.


Read moreShow less
https://twitter.com/spencerrascoff
https://www.linkedin.com/in/spencerrascoff/
admin@dot.la

This Week in ‘Raises’: Measurabl Snags $93M, Selva Ventures Grabs $34M

Decerry Donato

Decerry Donato is a reporter at dot.LA. Prior to that, she was an editorial fellow at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.

Raises
Image by Joshua Letona

A local data management platform company lands fresh funding to help commercial real estate owners reduce carbon footprint, while one Los Angeles-based venture firm closes its second fund to accelerate the growth of emerging companies across health, wellness, beauty and personal care.

***

Read moreShow less

McKinsey & Company Launches InLA Accelerator To Help Underrepresented Founders Tackle Startup Challenges

Decerry Donato

Decerry Donato is a reporter at dot.LA. Prior to that, she was an editorial fellow at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.

McKinsey & Company Launches InLA Accelerator To Help Underrepresented Founders Tackle Startup Challenges
InLA

In 2022, female founders saw a 28% decline in overall U.S. funding, while Black-led startups saw a 38% decline in total capital received. In an effort to increase funding for minority-led startups, global venture firm McKinsey & Company is launching InLA, an accelerator program for underrepresented founders.

“This effort is something that the firm has been really excited about for a long time,” Engagement Manager Elkhyn Rivas Rodriguez said. “There's obviously a meaningful and growing startup community out here and just from a diversity standpoint, LA is incredibly diverse and multi-ethnic and multicultural. So we think that there will be a really great pool of potential companies to partner with.”

Read moreShow less
RELATEDEDITOR'S PICKS
LA TECH JOBS
interchangeLA
Trending